US pharmaceutical giant Pfizer could make a hostile bid for AstraZeneca as early as today.
Its £63 billion takeover offer was rejected after the UK company said it "substantially" undervalued the business.
That has forced Pfizer to consider its next move, with industry experts believing a hostile bid - which would aim to bypass the AstraZeneca management and target shareholders directly - could come soon.
Last week, Pfizer insisted it was committed to building a research and development hub in Cambridge which was planned by AstraZeneca.
The £300m base at the Cambridge Biomedial Campus would house about 2,000 researchers.
But a hostile bid would trigger increased calls for the offer to be referred to the competition authorities and would also heighten union fears over jobs if the takeover was successful.
More top news
A campaign has been launched to increase tourism revenue in Northamptonshire by 50% - masterminded by a former Saatchi & Saatchi director.
A change in wind direction brings warmer temperatures to the Anglia region
The RSPCA is investigating after two thin dogs were found abandoned, in a neglected state, on an isolated road in Hertfordshire.